Published in Am J Cancer Res on June 28, 2012
Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. Int J Mol Sci (2012) 1.44
Heat shock protein 27 phosphorylation state is associated with cancer progression. Front Genet (2014) 0.97
Inhibition of p38 mitogen-activated protein kinase alters microRNA expression and reverses epithelial-to-mesenchymal transition. Int J Oncol (2013) 0.86
TRAIL combinations: The new 'trail' for cancer therapy (Review). Oncol Lett (2014) 0.85
Elevated expression of long intergenic non-coding RNA HOTAIR in a basal-like variant of MCF-7 breast cancer cells. Mol Carcinog (2014) 0.81
P38 MAPK contributes to resistance and invasiveness of HER2- overexpressing breast cancer. Curr Med Chem (2014) 0.79
Tumor p38MAPK signaling enhances breast carcinoma vascularization and growth by promoting expression and deposition of pro-tumorigenic factors. Oncotarget (2017) 0.75
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev (2001) 13.15
Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer (2009) 5.89
Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat (2004) 4.89
p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta (2007) 4.80
Mechanisms and functions of p38 MAPK signalling. Biochem J (2010) 4.59
Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer (2002) 4.57
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res (2008) 3.32
Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol (2005) 3.18
Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol (1996) 2.83
Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene (2003) 2.82
Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res (2006) 2.63
Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev (1998) 2.50
Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev (2003) 2.39
Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ (2001) 2.27
Fra-1 induces morphological transformation and increases in vitro invasiveness and motility of epithelioid adenocarcinoma cells. Mol Cell Biol (1998) 2.22
Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res (2004) 2.15
Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res (2001) 2.01
Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol (2005) 2.01
Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res (2002) 1.92
A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm. Nature (2002) 1.89
Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res (2003) 1.89
Induction of apoptosis by SB202190 through inhibition of p38beta mitogen-activated protein kinase. J Biol Chem (1998) 1.87
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer (2005) 1.81
FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells. Oncogene (2005) 1.74
Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation. Mol Cell Biol (2002) 1.67
MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer. Oncogene (2006) 1.60
COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer (2004) 1.59
Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Cancer Res (2001) 1.55
Neoplastic transformation of rat thyroid cells requires the junB and fra-1 gene induction which is dependent on the HMGI-C gene product. EMBO J (1997) 1.51
Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clin Cancer Res (2003) 1.50
Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J Clin Oncol (2008) 1.47
MEKK3 directly regulates MEK5 activity as part of the big mitogen-activated protein kinase 1 (BMK1) signaling pathway. J Biol Chem (1999) 1.47
Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res (2010) 1.45
Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway. Oncogene (2003) 1.43
Feedback regulation of p38 activity via ATF2 is essential for survival of embryonic liver cells. Genes Dev (2007) 1.43
p38 kinase is a key signaling molecule for H-Ras-induced cell motility and invasive phenotype in human breast epithelial cells. Cancer Res (2003) 1.40
The repertoire of fos and jun proteins expressed during the G1 phase of the cell cycle is determined by the duration of mitogen-activated protein kinase activation. Mol Cell Biol (1999) 1.39
Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat (1993) 1.36
Fra-1 a target for cancer prevention or intervention. Gene (2006) 1.35
Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer (2010) 1.31
Increased ROS levels contribute to elevated transcription factor and MAP kinase activities in malignantly progressed mouse keratinocyte cell lines. Carcinogenesis (1999) 1.31
Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. Endocrinology (2010) 1.29
Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. Breast Cancer Res Treat (2009) 1.29
The p38-MAPK inhibitor, SB203580, inhibits cardiac stress-activated protein kinases/c-Jun N-terminal kinases (SAPKs/JNKs). FEBS Lett (1998) 1.28
RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J Pharmacol Exp Ther (1999) 1.26
Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biol Ther (2011) 1.24
Analysis of AP-1 function in cellular transformation pathways. J Virol (1994) 1.18
Identification of the potent phytoestrogen glycinol in elicited soybean (Glycine max). Endocrinology (2008) 1.15
p38 regulates cyclooxygenase-2 in human mammary epithelial cells and is activated in premalignant tissue. Cancer Res (2005) 1.15
Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer. Int J Cancer (2002) 1.14
Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocr Relat Cancer (2005) 1.09
Single-dose pharmacokinetics and pharmacodynamics of RWJ 67657, a specific p38 mitogen-activated protein kinase inhibitor: a first-in-human study. J Clin Pharmacol (2003) 1.07
Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling. Int J Oncol (2004) 1.04
FRA-1 protein overexpression is a feature of hyperplastic and neoplastic breast disorders. BMC Cancer (2007) 1.03
p38 mitogen-activated protein kinase stimulates estrogen-mediated transcription and proliferation through the phosphorylation and potentiation of the p160 coactivator glucocorticoid receptor-interacting protein 1. Mol Endocrinol (2006) 1.02
Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium. Cancer Res (2003) 1.00
Organochlorine-mediated potentiation of the general coactivator p300 through p38 mitogen-activated protein kinase. Carcinogenesis (2008) 1.00
Pattern of hormone receptor status of secondary contralateral breast cancers in patients receiving adjuvant tamoxifen. Clin Cancer Res (2002) 1.00
Regulation of stress-responsive mitogen-activated protein (MAP) kinase pathways by TAO2. J Biol Chem (2001) 1.00
Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer. J Mol Endocrinol (2011) 0.99
Strong inhibition of TNF-alpha production and inhibition of IL-8 and COX-2 mRNA expression in monocyte-derived macrophages by RWJ 67657, a p38 mitogen-activated protein kinase (MAPK) inhibitor. Arthritis Res Ther (2004) 0.98
Modulation of estrogen receptor activity by selective coregulators. J Steroid Biochem Mol Biol (2003) 0.94
Mechanism of AP-1-mediated gene expression by select organochlorines through the p38 MAPK pathway. Carcinogenesis (2003) 0.94
Alpha(v) integrin, p38 mitogen-activated protein kinase, and urokinase plasminogen activator are functionally linked in invasive breast cancer cells. J Biol Chem (2001) 0.93
AKT regulation of estrogen receptor beta transcriptional activity in breast cancer. Cancer Res (2006) 0.93
p38beta MAP kinase protects rat mesangial cells from TNF-alpha-induced apoptosis. J Cell Biochem (2001) 0.91
SB203580, a pharmacological inhibitor of p38 MAP kinase transduction pathway activates ERK and JNK MAP kinases in primary cultures of human hepatocytes. Eur J Pharmacol (2008) 0.91
Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer. Biochim Biophys Acta (2008) 0.89
Novel D: -erythro N-octanoyl sphingosine analogs as chemo- and endocrine-resistant breast cancer therapeutics. Cancer Chemother Pharmacol (2010) 0.89
A p38 MAP kinase inhibitor SB203580 inhibits CD28-dependent T cell proliferation and IL-2 production. Biochem Soc Trans (1997) 0.88
p38 MAPK inhibitors, IKK2 inhibitors, and TNFα inhibitors in COPD. Curr Opin Pharmacol (2012) 0.88
Mitogen-activated protein kinase cascade in breast cancer. Oncology (1999) 0.83
Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs). Breast Cancer Res (2003) 0.81
Chapel Hill bisphenol A expert panel consensus statement: integration of mechanisms, effects in animals and potential to impact human health at current levels of exposure. Reprod Toxicol (2007) 4.04
In vitro molecular mechanisms of bisphenol A action. Reprod Toxicol (2007) 3.69
Why public health agencies cannot depend on good laboratory practices as a criterion for selecting data: the case of bisphenol A. Environ Health Perspect (2008) 3.27
The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone. J Cell Biol (2004) 2.41
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Res (2011) 2.13
Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood (2010) 1.84
Female reproductive disorders: the roles of endocrine-disrupting compounds and developmental timing. Fertil Steril (2008) 1.60
Epigenetics, evolution, endocrine disruption, health, and disease. Endocrinology (2006) 1.60
Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Res (2012) 1.51
Environmental exposure, DNA methylation, and gene regulation: lessons from diethylstilbesterol-induced cancers. Ann N Y Acad Sci (2003) 1.50
Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res (2010) 1.45
Differences in gastric carcinoma microenvironment stratify according to EBV infection intensity: implications for possible immune adjuvant therapy. PLoS Pathog (2013) 1.43
Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis (2010) 1.42
Absence of functional EpoR expression in human tumor cell lines. Blood (2010) 1.41
MEK5/ERK5 pathway: the first fifteen years. Biochim Biophys Acta (2011) 1.39
Patients with spina bifida and bladder cancer: atypical presentation, advanced stage and poor survival. J Urol (2007) 1.38
Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. Breast Cancer Res (2008) 1.35
Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis. Clin Cancer Res (2006) 1.31
Neonatal diethylstilbestrol exposure induces persistent elevation of c-fos expression and hypomethylation in its exon-4 in mouse uterus. Mol Carcinog (2003) 1.30
Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. Endocrinology (2010) 1.29
Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. Breast Cancer Res Treat (2009) 1.29
Novel ceramide analogs as potential chemotherapeutic agents in breast cancer. J Pharmacol Exp Ther (2004) 1.28
Identification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray. Surgery (2002) 1.27
Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biol Ther (2011) 1.24
Identification of the potent phytoestrogen glycinol in elicited soybean (Glycine max). Endocrinology (2008) 1.15
Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration. Breast Cancer Res (2012) 1.14
Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk. Mol Cancer (2010) 1.08
Pesticides reduce symbiotic efficiency of nitrogen-fixing rhizobia and host plants. Proc Natl Acad Sci U S A (2007) 1.07
NF-kappaB plays a key role in hypoxia-inducible factor-1-regulated erythropoietin gene expression. Exp Hematol (2002) 1.05
A new method for stranded whole transcriptome RNA-seq. Methods (2013) 1.05
Developmental diethylstilbestrol exposure alters genetic pathways of uterine cytodifferentiation. Mol Endocrinol (2004) 1.05
Role of PELP1/MNAR signaling in ovarian tumorigenesis. Cancer Res (2008) 1.05
Glyceollin I, a novel antiestrogenic phytoalexin isolated from activated soy. J Pharmacol Exp Ther (2009) 1.05
Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling. Int J Oncol (2004) 1.04
Evaluation of the estrogenic effects of legume extracts containing phytoestrogens. J Agric Food Chem (2003) 1.03
Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway. Breast Cancer Res (2010) 1.03
p38 mitogen-activated protein kinase stimulates estrogen-mediated transcription and proliferation through the phosphorylation and potentiation of the p160 coactivator glucocorticoid receptor-interacting protein 1. Mol Endocrinol (2006) 1.02
Regulation of ERalpha-mediated transcription of Bcl-2 by PI3K-AKT crosstalk: implications for breast cancer cell survival. Int J Oncol (2010) 1.01
Endocrine disruptor regulation of microRNA expression in breast carcinoma cells. PLoS One (2012) 1.00
Organochlorine-mediated potentiation of the general coactivator p300 through p38 mitogen-activated protein kinase. Carcinogenesis (2008) 1.00
Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer. J Mol Endocrinol (2011) 0.99
Design, synthesis, and biological activity of a family of novel ceramide analogues in chemoresistant breast cancer cells. J Med Chem (2009) 0.98
Epigallocatechin-3 gallate induces growth inhibition and apoptosis in human breast cancer cells through survivin suppression. Int J Oncol (2007) 0.98
The robotic approach to complex hepatobiliary anomalies in children: preliminary report. J Pediatr Surg (2007) 0.97
Environmental hormones: Multiple pathways for response may lead to multiple disease outcomes. Steroids (2010) 0.97
Detecting ligands and dissecting nuclear receptor-signaling pathways using recombinant strains of the yeast Saccharomyces cerevisiae. Nat Protoc (2008) 0.96
Toxoplasma gondii expresses two mitogen-activated protein kinase genes that represent distinct protozoan subfamilies. J Mol Evol (2006) 0.96
Obesity associated alterations in the biology of adipose stem cells mediate enhanced tumorigenesis by estrogen dependent pathways. Breast Cancer Res (2013) 0.96
A multiplexed proteomics approach to differentiate neurite outgrowth patterns. J Neurosci Methods (2006) 0.96
Effects of soybean glyceollins and estradiol in postmenopausal female monkeys. Nutr Cancer (2006) 0.95
The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells. Oncol Rep (2011) 0.95
Mechanism of AP-1-mediated gene expression by select organochlorines through the p38 MAPK pathway. Carcinogenesis (2003) 0.94
Preferential star strand biogenesis of pre-miR-24-2 targets PKC-alpha and suppresses cell survival in MCF-7 breast cancer cells. Mol Carcinog (2012) 0.94